Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence
Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence
复制标题
DOI：
10.1200/jco.2005.04.8280
复制
发表时间：
2006-07-01
影响因子：
45.3
通讯作者：
Russo, Paul
中科院分区：
文献类型：
--
作者：
Eggener, Scott E.;Yossepowitch, Ofer;Russo, Paul
良好确定了转移性肾细胞癌（RCC）患者的目的预后因素。然而，肾切除术后复发性RCC患者的局部疾病患者和方法从1989年1月至2005年7月尚不清楚风险特征。我们应用了以前针对转移性RCC患者开发的经过验证的预后评分系统。每位患者的总风险评分为0至5，五个预后变量中的每一个点（肾切除术后复发<12个月，血清钙> 10 mg/dL，血红蛋白<正常，乳酸脱氢酶的下限> 1.5x正常的上限和Karnofsky性能状态<80％）。将患者分为低 - （得分= 0），中间 - （得分= 1至2）和高风险的亚组（得分= 3至5）。我们的最终队列包括118名患者，中位生存时间为21从复发开始的几个月。幸存者的中位随访时间为27个月。总体生存与风险组类别密切相关（P
Purpose Prognostic factors for patients with metastatic renal cell carcinoma (RCC) are well established. However, the risk profile is unknown for patients with recurrent RCC after a nephrectomy for localized disease.Patients and Methods From January 1989 to July 2005, we identified patients with localized RCC treated by nephrectomy who subsequently developed recurrent disease. We applied a validated prognostic scoring system previously developed for patients with metastatic RCC. Each patient was given a total risk score of 0 to 5, with one point for each of five prognostic variables (recurrence < 12 months after nephrectomy, serum calcium > 10 mg/dL, hemoglobin < lower limit of normal, lactate dehydrogenase > 1.5X upper limit of normal, and Karnofsky performance status < 80%). Patients were categorized into low- (score = 0), intermediate- (score = 1 to 2), and high-risk subgroups (score = 3 to 5).Results Our final cohort included 118 patients, with a median survival time of 21 Months from the time of recurrence. Median follow-up time for survivors was 27 months. Overall survival was strongly associated with risk group category (P